EGFR and breast cancer: In this study, we found for the first time that proguanil (Pro), which has the best bioactivity among biguanide drugs (phenformin, buformin, metformin, and proguanil) in seven BC cell lines [11], specifically targeted EGFR and enhanced its degradation to inhibit the proliferation of BC cells.